Deva Holding AS - Cerkezkoy Subesi recalls
FDA enforcement reports naming Deva Holding AS - Cerkezkoy Subesi as the recalling firm.
- Recall reports
- 6
- Class I (serious)
- 0
- Most recent report
- Jul 31, 2019
- Jul 31, 2019Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 67877-537-07), b) 14-co…Drug · Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.Class II
- Jul 31, 2019Temozolomide Capsules, 20 mg, packaged in a) 5-count bottle (NDC 67877-538-07), b) 14-c…Drug · Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.Class II
- Jul 31, 2019Temozolomide Capsules, 100 mg, packaged in a) 5-count bottle (NDC 67877-539-07), b) 14-…Drug · Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.Class II
- Jul 31, 2019Temozolomide Capsules, 140 mg, packaged in a) 5-count bottle (NDC 67877-540-07), b) 14-…Drug · Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.Class II
- Jul 31, 2019Temozolomide Capsules, 180 mg, packaged in a) 5-count bottle (NDC 67877-541-07), b) 14-…Drug · Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.Class II
- Jul 31, 2019Temozolomide Capsules, 250 mg, 5-count bottle, Rx only, Manufactured by: Deva Holding ADrug · Deva Holding AS - Cerkezkoy SubesiCGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.Class II